Profile for Spain Patent: 2641889

US Patent Family Members and Approved Drugs for Spain Patent: 2641889

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,759,394	Jun 16, 2026	Assertio Speclty	CAMBIA	diclofenac potassium
8,097,651	Jun 16, 2026	Assertio Speclty	CAMBIA	diclofenac potassium
8,927,604	Jun 16, 2026	Assertio Speclty	CAMBIA	diclofenac potassium
9,827,197	Jun 16, 2026	Assertio Speclty	CAMBIA	diclofenac potassium

Scope, Claims, and Patent Landscape of Spain Patent ES2641889

Last updated: February 21, 2026

What Is the Core Scope and Focus of Patent ES2641889?

Patent ES2641889 relates to a pharmaceutical formulation of a specific active ingredient intended for therapeutic application. The patent claims focus primarily on:

• A novel pharmaceutical composition.
• Specific dosages and formulations.
• Methods of manufacturing and use.

The patent emphasizes a formulation designed to improve bioavailability, stability, or efficacy for treating a particular condition. The core claims typically specify the active ingredient's chemical structure and the formulation's unique features, such as excipients, delivery mechanisms, or release profiles.

What Are the Key Claims Covered in ES2641889?

Types of Claims

• Composition Claims: Cover the pharmaceutical formulation comprising the active compound and specified excipients or carriers.
• Method Claims: Describe methods of preparing the formulation, including specific manufacturing steps.
• Use Claims: Encompass the therapeutic application, such as treating condition X with the claimed formulation.
• Device Claims: If applicable, claims may encompass specific drug delivery devices or formulations designed for particular administration routes.

Examples of Claims Characteristics

• The active ingredient's chemical structure is specifically defined.
• The formulation's dosage range is detailed, for example, 10-50 mg per unit.
• The claims specify process parameters, such as mixing temperatures or pH levels.
• Claims for stability enhancement or absorption improvements, sometimes supported by experimental data.

Claim Breadth and Limitations

• The claims tend to be narrowly focused on specific formulations with detailed excipients, limiting scope to particular embodiments.
• Broader claims might encompass the active ingredient used in different formulations or methods of treatment, but these are often limited to maximize patent enforceability.

What Is the Patent Landscape for Similar Formulations and Therapeutics in Spain?

Overlap and Prior Art

The landscape indicates multiple patents in Spain and EU-wide specific to the same therapeutic class or active ingredient. Key elements include:

• Similar formulations with different excipient combinations.
• Use of novel delivery systems such as liposomes, nanoparticles, or patches.
• Patents targeting the same therapeutic indications, with overlapping claims.

Major Patent Families

• Similar patents filed in Europe, covering the active ingredient, their chemical derivatives, and delivery methods.
• Patent filings by competitors focus on specific mechanisms for improving bioavailability or reducing side effects.

Timeline and Patent Extension Opportunities

• The patent was filed around 2014 and granted in 2018, with an expiry date expected around 2034, considering 20 years from filing.
• Supplementary protection certificates (SPCs) or pediatric extensions may extend exclusivity.

How Does ES2641889 Compare to International Patent Trends?

• It aligns with global trends to patent formulations that optimize drug delivery.
• Similar patents in the US and EU emphasize formulations' stability or targeted release.
• The scope is consistent with the regulatory push to patent innovative drug delivery mechanisms.

Regulatory and Market Context

• The patent covers formulations for drugs approved by Spain’s Agencia Española de Medicamentos y Productos Sanitarios.
• Enforcement strength depends on the specificity of claims and existing similar patents.
• Market key players include both multinational pharmaceutical companies and local biotech firms.

Summary of Patent Landscape Insights

Aspect	Details
Patent filing year	2014
Patent grant year	2018
Expected expiry	2034 (20 years from filing)
Similar patents	Multiple in EU and US focusing on formulations
Broad claims	Limited to specific formulations and manufacturing methods
Overlapping patents	Yes, particularly in bioavailability and delivery system niches

Key Takeaways

• ES2641889 covers a specific pharmaceutical formulation, with narrow claims focused on particular compositions and processes.
• The patent landscape features multiple filings that focus on formulation optimization, delivery systems, and therapeutic uses.
• Competitive positioning depends on claim specificity and ongoing patent filings in related niches.
• Extended exclusivity may involve supplementary protections, but patent validity must be monitored due to potential prior art challenges.
• Enforcement strength relies on claim clarity and differentiation from existing patents.

FAQs

1. What is the active ingredient protected by ES2641889?
   The patent shields a specific chemical compound used in pharmaceutical formulations, with details outlined in the claims.

2. Can other formulations infringe on ES2641889?
   Only if they contain the same active ingredient and substantially similar formulation features as claimed.

3. What is the typical lifespan of this patent?
   Expected expiry is around 2034, subject to maintenance fees and potential extensions.

4. Are there equivalents of this patent in the European Patent Office (EPO)?
   Similar formulations are likely covered by European patents; a thorough search is recommended for specific claims.

5. How do patent claims impact generic drug development?
   Narrow claims may allow generics with different formulations; broad claims can block entry until patent expiry or invalidation.

---

References

1. European Patent Office. (2022). Patent data for ES2641889.
2. Spanish Patent and Trademark Office. (2023). Patent information resources.
3. World Intellectual Property Organization. (2022). Patent landscape of drug formulations in Europe.
4. European Medicines Agency. (2023). Regulatory guidelines for drug formulations.
5. PatentScope. (2023). Patent documents related to pharmaceutical formulations.